Clover Biopharma Begins Patient Dosing In Phase 1 Trial With Scb-2020S, A Potentially Broadly Protective Chimeric Covid-19 Vaccine Candidate
Clover Biopharmaceuticals, Ltd., A Global Clinical-Stage Biotechnology Company, Announced The First Participants Have Been Dosed In A Phase 1 Clinical Trial To Assess The Safety And Immunogenicity Of Several Formulations Of Scb-2020S. Scb-2020S Is A Second Generation, Potentially Broadly Protective Covid-19 Vaccine Candidate Based On A Chimeric Beta And Prototype Trimeric Sars-Cov-2 S-Protein, Preserving Potential Neutralization Epitopes Across Multiple Variants Of Concern (Vocs) Of Sars-Cov-2, Including Omicron. Clover Intends To Explore How The Scb-2020S Construct Could Further Expand The Breadth Of Vaccine-Induced Neutralizing Antibodies To Address The Existing And Potential New Variant Strains Of The Sars-Cov-2 Virus.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
